Galleri Test
Galleri Cancer Test
CANCER SCREENING IS KEY
Why Early Cancer Detection is Important
As you know, you and your health are our first priority here at Regen Wellness, which is why we want to tell you more about a novel multi-cancer early detection test we’re now offering.
Introducing the Galleri™ test*—an innovative breakthrough in early cancer detection that detects more than 50 types of cancer, many of which are not commonly screened for today.
Here are a couple reasons why multi-cancer early detection is so important:
- If detected early, more treatment options may be available which may improve outcomes and survival rates.3
- Today, 71% of cancer deaths are caused by cancer not commonly screened for.
Schedule a FREE consult to find out if the Galleri test is right for you.
Beating cancer starts with knowing you have it
Benefits of Early Cancer Detection
You may have seen recent news about advances in early cancer detection. We're excited to share that we now offer a revolutionary multi-cancer early detection test for our patients.
It’s called the Galleri Multi-Cancer Early-Detection Test* and it can detect more than 50 types of cancer by looking for signals in the blood that may be associated with cancer. If caught in its early stages, cancer treatment outcomes and survival rates may be improved.3
Here are a few benefits of the test:
- It detects many cancers that are not commonly screened for today, so you can get treated earlier.
- It can be incorporated into a routine visit through a simple blood draw.
- If a cancer signal is found, the results point to where in the body the cancer is coming from to help us guide your next steps
With a simple blood draw, the Galleri test can provide early detection insights that help you to be proactive about your health.
When cancer is diagnosed early before it has had a chance to spread, the overall 5-year survival rate is 4 times higher than when it's diagnosed in later stages.
Sources:
1. Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test. Abstract LB013. Presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting April 10 – 15, 2021.
2. Amin MB, et al. (Eds). American Joint Committee of Cancer (AJCC) Cancer Staging Manual (8th edition)
3. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 18 Regs Research Data, Nov 2018 . Includes persons aged 50-79 diagnosed 2006-2015 “Early/Localized” includes invasive localized tumors that have not spread beyond organ of origin, “Late/Metastasized” includes invasive cancers that have metastasized beyond the organ of origin to other parts of the body.
4 Modeled detection extrapolated to 2020 US population ages 50–79. Screening includes methods with United States Preventive Services Task Force (USPSTF) A, B, or C rating (breast, colon, cervical, prostate, and lung), and assumes screening is available for all prostate, breast, cervical, and colorectal cancer cases and 33% of lung cancer cases (based on estimated proportion of lung cancers that occur in screen-eligible individuals older than 40 years).
5 Data on file from Surveillance, Epidemiology, and End Results (SEER) 18 Regs Research Data, Nov 2017 Submission. Includes persons aged 50–79. Estimated deaths per year in 2020 from American Cancer Society Cancer Facts and Figures 2020. Available at: www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2020/cancer-facts-and-figures-2020.pdf